ReviewMaterials today. Bio2025
Transforming spinal surgery with innovations in biologics and additive manufacturing.
Review in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Biomaterial strategies for precision regeneration of the tooth extraction socket: integrating site phenotype, pathological microenvironment, and healing sequence.Frontiers in bioengineering and biotechnology · 2026Review
- Morphological characteristics of lumbar vertebral bodies and regional distribution patterns of bone mineral density: a CT study.Frontiers in physiology · 2026Article
- Advancements in biomaterials and bioactive solutions for lumbar spine fusion cages: Current trends and future perspectives.Bioactive materials · 2025Review
- Review
Corrections and comments
- Erratum issued
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The synergistic integration of biologics and additive manufacturing (AM) technologies has catalyzed groundbreaking advancements in spinal surgery. These innovations address persistent challenges, such as optimizing fusion outcomes, enhancing tissue regeneration, and achieving precise anatomical compatibility. Biologics have transformed spinal fusion by facilitating bone formation and promoting osteointegration through refinements in traditional materials and cutting-edge biologic developments. Concurrently, AM technologies, including 3D printing and biofabrication, enable the design and production of patient-specific implants and bioengineered scaffolds, significantly enhancing surgical precision and improving treatment outcomes. This review underscores the transformative synergy of biologics and AM, offering a comprehensive exploration of their applications in preclinical research and clinical practice. Together, these synergistic advancements are redefining the field of spinal surgery, driving the evolution of personalized and innovative treatment paradigms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.